Gedatolisib (Standard)

• Description :

  Gedatolisib (Standard) is the analytical standard of Gedatolisib. This product is intended for research and analytical applications. Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively[1]. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2[2].

• UNSPSC :

  12352100

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  MTOR; PI3K; Reference Standards

• Related Pathways :

  Others; PI3K/Akt/mTOR

• Field of Research :

  Cancer

• Purity :

  97.70

• Smiles :

  CN(C1CCN(C(C2=CC=C(NC(NC3=CC=C(C4=NC(N5CCOCC5)=NC(N6CCOCC6)=N4)C=C3)=O)C=C2)=O)CC1)C

• Molecular Formula :

  C32H41N9O4

• Molecular Weight :

  615.73

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Venkatesan AM, et al. Bis (morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem. 2010, 53 (6), 2636-2645.|[2]Freitag H, et al. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease. Neuroendocrinology. 2017;105 (1) :90-104.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, sealed storage, away from light and moisture

• Scientific Category :

  Reference Standards

• Clinical Information :

  No Development Reported

• CAS Number :

  [1197160-78-3]